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However, the majority of patients will eventually relapse, necessitating salvage therapy.
HOVON-86 is a dose-escalating phase I-II study, evaluating the feasibility (phase I) and efficacy (phase II) of once-weekly escalated doses of bortezomib and lenalidomide in combination with fixed dose dexamethasone followed by lenalidomide maintenance in patients with MM in first relapse or refractory after first-line therapy. In previous trials bortezomib was explored predominantly in a twiceweekly schedule. We wished to explore once-weekly bortezomib with the possibility to increase the dose of bortezomib in combination with an escalated dose of lenalidomide and dexamethasone.
The maximum tolerated dose (MTD) and recommended dose level (RDL) were determined according to a `3+3' dose-escalation scheme at bortezomib 1.6mg/m 2 intravenously (IV); lenalidomide 10mg; dexamethasone 20mg, followed by lenalidomide maintenance.
44 out of 70 (63%) eligible patients started maintenance. ORR on protocol was 89%, with 71% ≥ VGPR, including 27% CR. The median number of cycles to achieve In patients who had achieved at least VGPR after a maximum of 6 cycles, treatment was continued with 2 cycles as consolidation. All patients from phase I and phase II who had achieved at least a PR after induction, received maintenance with lenalidomide at a dose of 10 mg days 1-21, which started at day 29 of the last cycle. Maintenance cycles were repeated at 28-days intervals until relapse, progression or the occurrence of a medical condition that required stopping the treatment. 49/70 patients (70%) went off-protocol, while the remaining 21 (30%) patients were still receiving maintenance treatment at the time of data analysis. The main reasons for going off-protocol were progression or relapse (n=25/70) (36%) and/or toxicity (n=12/70) (17%).
Of 70 patients treated at the RDL in phase I (n=6) and in phase II (n=64), the (s)CR +VGPR rate after induction was 64% (95%CI: 53%-76%), including 20% CR (95%CI:10%-30%). The ORR was 89%
(95%CI: 81%-96%). The median number of cycles to reach at least a PR was 1 (range 1-6). The median number of cycles to best response during induction was 2 (range 1-8).
Analysis of PFS and OS measured from study entry was available for all patients. lenalidomide15 mg/day and dexamethasone followed by maintenance therapy. ORR was 64%
including patients who had been exposed to either agent alone. The median PFS and OS at a median follow-up of 44 months were 9.5 and 30 months, respectively. 10 The comparisons across studies should be interpreted with caution because of potential confounding factors such as differences in patient characteristics and prior therapies, as mentioned.
We observed that the higher dose bortezomib (1.6 mg/m 2 weekly) was associated with 17% grade 3-4 PN, higher than observed in the study by Richardson et al. reporting an incidence of 3% grade 3 PN using a bortezomib dose of 1.0 mg/m 2 . 10, 11 Of note, in our study bortezomib was administered IV, which is different from the current standard, i.e. 1.3 mg/m 2 subcutaneously.
Weekly escalated dose bortezomib of 1.6 mg/m2 plus lenalidomide 10 mg/day, combined with lowdose dexamethasone is a feasible, effective treatment for relapsed, refractory MM patients. Future applications of this schedule may benefit from subcutaneous dosing in order to reduce the incidence of PN. Yes  ------5  8%  5  6%  unknown  2  100%  4  67%  3  60%  19  30%  28  36%  extra copy of 9  and/or 11  No  1  50%  2  33%  --24  38%  27  35%  Yes  1  50%  1  17%  2  40%  17  27%  21  27%  unknown  --3  50%  3  60%  23  36%  29  38% 
